Last reviewed · How we verify

Florbetapir F 18 (18F-AV-45) — Competitive Intelligence Brief

Florbetapir F 18 (18F-AV-45) (Florbetapir F 18 (18F-AV-45)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PET imaging agent. Area: Neurology / Alzheimer's disease.

marketed PET imaging agent Amyloid-beta (Aβ) plaques Neurology / Alzheimer's disease Small molecule Live · refreshed every 30 min

Target snapshot

Florbetapir F 18 (18F-AV-45) (Florbetapir F 18 (18F-AV-45)) — University of California, San Francisco. Florbetapir F-18 is a positron emission tomography (PET) imaging agent that binds to amyloid-beta plaques in the brain to detect Alzheimer's disease pathology.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Florbetapir F 18 (18F-AV-45) TARGET Florbetapir F 18 (18F-AV-45) University of California, San Francisco marketed PET imaging agent Amyloid-beta (Aβ) plaques
Flotufolastat (18F) Flotufolastat (18F) Blue Earth Diagnostics marketed Folate receptor-targeted PET imaging agent Folate receptor alpha (FR-α)
[F-18]-Fludeoxyglucose [F-18]-Fludeoxyglucose University of Saskatchewan marketed Radiopharmaceutical; PET imaging agent Glucose transporter (GLUT1); hexokinase
C-11 labeled nicotine C-11 labeled nicotine University of Cincinnati marketed PET imaging agent / radiotracer Nicotinic acetylcholine receptors
Neuraceq (florbetaben 18F) Neuraceq (florbetaben 18F) Piramal Imaging Limited marketed PET imaging agent Amyloid-beta plaques
Fluciclovine PET/CT Fluciclovine PET/CT OHSU Knight Cancer Institute marketed PET imaging agent Amino acid transporters (LAT1, ASCT2)
18F-rhPSMA-7.3 18F-rhPSMA-7.3 Hackensack Meridian Health marketed PET imaging agent / radiopharmaceutical PSMA (prostate-specific membrane antigen)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PET imaging agent class)

  1. University of California, San Francisco · 2 drugs in this class
  2. Central Hospital, Nancy, France · 1 drug in this class
  3. Centre hospitalier de l'Université de Montréal (CHUM) · 1 drug in this class
  4. Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · 1 drug in this class
  5. Institute for Neurodegenerative Disorders · 1 drug in this class
  6. OHSU Knight Cancer Institute · 1 drug in this class
  7. Piramal Imaging Limited · 1 drug in this class
  8. SOFIE · 1 drug in this class
  9. Universidad Central del Caribe · 1 drug in this class
  10. University of California, Irvine · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Florbetapir F 18 (18F-AV-45) — Competitive Intelligence Brief. https://druglandscape.com/ci/florbetapir-f-18-18f-av-45. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators: